PVLA
Palvella Therapeutics Inc.
$79.84
+$1.42(+1.81%)
65
Overall
50
Value
91
Tech
55
Quality
Market Cap
$812.89M
Volume
170.93K
52W Range
$11.17 - $80.79
Target Price
$82.83
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $23.9M | $27.9M | $25.5M | $38.7M | -- | ||
| Total Revenue | $29.3M | $31.4M | $25.9M | $42.8M | -- | ||
| GROSS PROFIT | |||||||
| Gross Profit | $29.3M | $31.4M | $25.5M | $42.8M | -- | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $63.2M | $83.2M | $61.2M | $11.9M | $14.1M | ||
| Research & Development | $46.5M | $66.7M | $53.0M | $8.8M | $8.2M | ||
| Research Expense | $46.5M | $66.7M | $53.0M | $8.8M | $8.2M | ||
| Selling, General & Administrative | $16.7M | $16.6M | $16.4M | $3.1M | $5.9M | ||
| General & Administrative Expenses | $16.7M | $16.6M | $16.4M | $3.1M | $5.9M | ||
| Salaries & Wages | -- | -- | -- | $603.0K | $830.0K | ||
| Depreciation & Amortization | $2.1M | $2.4M | $2.3M | $1.8M | -- | ||
| Depreciation & Amortization | $2.1M | $2.4M | $2.3M | $1.8M | -- | ||
| Amortization | $100.0K | -- | -- | -- | -- | ||
| Other Operating Expenses | $2.2M | $2.2M | $2.1M | $1.8M | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-33.9M | $-51.8M | $-43.9M | $-11.9M | $-14.1M | ||
| EBITDA | $-34.9M | $-47.0M | $-32.5M | $18.7M | $-17.0M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $4.3M | ||
| Interest Income Operating | -- | -- | $8.2M | -- | -- | ||
| Intinc | $511.0K | $4.0K | $721.0K | $1.9M | -- | ||
| Net Non-Operating Interest Income/Expense | $511.0K | $4.0K | $721.0K | $1.9M | $-430.0K | ||
| Gain on Sale of Securities | $-600.0K | -- | $400.0K | $485.0K | $-633.0K | ||
| Other Income/Expense | $-1.8M | $-5.9M | $1.3M | $-24.3M | $-978.0K | ||
| Other Special Charges | $1.8M | $5.9M | $1.7M | $23.8M | $511.0K | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | -- | $8.2M | $-13.9M | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $13.9M | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-37.1M | $-49.4M | $-35.3M | $18.7M | $-13.1M | ||
| Pre-Tax Income | $-37.1M | $-49.4M | $-33.3M | $18.7M | $-17.4M | ||
| INCOME TAX | |||||||
| Tax Provision | $164.0K | -- | -- | -- | -- | ||
| NET INCOME | |||||||
| Net Income | $-37.2M | $-45.7M | $-33.3M | $18.7M | $-17.4M | ||
| Net Income (Continuing Operations) | $-37.2M | $-45.7M | $-33.3M | $18.7M | $-17.4M | ||
| Net Income (Discontinued Operations) | $-37.2M | $-45.7M | $-33.3M | $18.7M | $-17.4M | ||
| Net Income (Common Stockholders) | $-37.2M | $-49.4M | $-33.3M | $17.9M | $-17.4M | ||
| Normalized Income | -- | $-39.0M | -- | -- | -- | ||
| TOTALS | |||||||
| Total Expenses | $63.2M | $83.2M | $61.2M | $11.9M | $14.1M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $54.5M | $64.5M | $74.2M | $1.1M | $2.2M | ||
| Average Shares Outstanding (Diluted) | $54.5M | $64.5M | $74.2M | $1.1M | $2.2M | ||
| Shares Outstanding | $59.7M | $74.1M | $74.5M | $1.2M | $11.0M | ||
| Basic EPS | $-0.68 | $-0.71 | $-0.45 | $-21.6 | $-7.83 | ||
| Basic EPS (Continuing Operations) | $-0.68 | $-0.71 | $-0.45 | $-21.6 | $-7.83 | ||
| Diluted EPS | $-0.68 | $-0.71 | $-0.45 | $-21.6 | $-7.83 | ||
| Diluted EPS (Continuing Operations) | -- | $-0.71 | -- | -- | $-7.83 | ||
| OTHER METRICS | |||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | $776.0K | -- | ||
| Acquired In Process Rn D | -- | -- | $8.2M | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | $3.6M | -- | ||
| Other Gand A | $16.7M | $16.6M | $16.4M | $3.1M | $5.9M | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | $776.0K | -- | ||
| Preferred Stock Dividends | -- | -- | -- | $776.0K | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PVLA | $79.84 | +1.8% | 170.93K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Palvella Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW